Despite the poor survival outcome of BRAF V600E-mutant NSCLC patients as compared to patients with wild-type BRAF [8], treatment with BRAF inhibitors have significantly improved their prognosis. The gene discussed is BRAF; the disease is non-small cell lung carcinoma.